A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing

Peking University Third Hospital /ID# 228138, Beijing

Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 227724, Shanghai

The First Affiliated Hospital of Soochow University /ID# 228024, Suzhou

The Affiliated Hospital of Xuzhou Medical College /ID# 228774, Xuzhou

Tianjin Cancer Hospital /ID# 228135, Tianjin

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 228154, Hangzhou

Zhejiang Cancer hospital /ID# 228776, Hangzhou

The First Affiliated Hospital of Nanchang University /ID# 228771, Nanchang

Jiangxi Provincial Cancer Hospital /ID# 231944, Nanchang

Fujian Medical University Union Hospital /ID# 231890, Fuzhou

Hunan Cancer Hospital /ID# 231859, Changsha

Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 231221, Wuhan

Henan Cancer Hospital /ID# 228772, Zhengzhou

Sun Yat-Sen University Cancer Center /ID# 228033, Guangzhou

Guangdong Provincial People's Hospital /ID# 228028, Guangzhou

Nanfang Hospital of Southern Medical University /ID# 227916, Guangzhou

West China Hospital, Sichuan University /ID# 231434, Chengdu